318 related articles for article (PubMed ID: 12011126)
1. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies.
Osterborg A; Brandberg Y; Molostova V; Iosava G; Abdulkadyrov K; Hedenus M; Messinger D;
J Clin Oncol; 2002 May; 20(10):2486-94. PubMed ID: 12011126
[TBL] [Abstract][Full Text] [Related]
2. Once weekly recombinant human erythropoietin treatment for cancer-induced anemia in children with acute lymphoblastic leukemia receiving maintenance chemotherapy: a randomized case-controlled study.
Abdelrazik N; Fouda M
Hematology; 2007 Dec; 12(6):533-41. PubMed ID: 17852440
[TBL] [Abstract][Full Text] [Related]
3. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response.
Cazzola M; Messinger D; Battistel V; Bron D; Cimino R; Enller-Ziegler L; Essers U; Greil R; Grossi A; Jäger G; LeMevel A; Najman A; Silingardi V; Spriano M; van Hoof A; Ehmer B
Blood; 1995 Dec; 86(12):4446-53. PubMed ID: 8541533
[TBL] [Abstract][Full Text] [Related]
4. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.
Littlewood TJ; Bajetta E; Nortier JW; Vercammen E; Rapoport B;
J Clin Oncol; 2001 Jun; 19(11):2865-74. PubMed ID: 11387359
[TBL] [Abstract][Full Text] [Related]
5. Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: epoetin treatment recommendations.
Ludwig H; Rai K; Blade J; Dammacco F; Degos L; Itri L; Kyle R; Liso V; Littlewood TJ; Mandelli F; Meloni G; Molica S; Osterborg A; Pangalis GA; San Miguel J; Schmitt B; Voliotis D
Hematol J; 2002; 3(3):121-30. PubMed ID: 12111647
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma--a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma.
Osterborg A; Boogaerts MA; Cimino R; Essers U; Holowiecki J; Juliusson G; Jäger G; Najman A; Peest D
Blood; 1996 Apr; 87(7):2675-82. PubMed ID: 8639883
[TBL] [Abstract][Full Text] [Related]
7. Epoetin alfa for the treatment of the anemia of multiple myeloma. A prospective, randomized, placebo-controlled, double-blind trial.
Garton JP; Gertz MA; Witzig TE; Greipp PR; Lust JA; Schroeder G; Kyle RA
Arch Intern Med; 1995 Oct; 155(19):2069-74. PubMed ID: 7575066
[TBL] [Abstract][Full Text] [Related]
8. Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production.
Cazzola M; Beguin Y; Kloczko J; Spicka I; Coiffier B
Br J Haematol; 2003 Aug; 122(3):386-93. PubMed ID: 12877665
[TBL] [Abstract][Full Text] [Related]
9. Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving non-platinum chemotherapy.
Littlewood TJ; Nortier J; Rapoport B; Pawlicki M; de Wasch G; Vercammen E; Schuette W; Wils J; Freund M;
Hematol Oncol; 2003 Dec; 21(4):169-80. PubMed ID: 14735555
[TBL] [Abstract][Full Text] [Related]
10. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
Voravud N; Sriuranpong V
J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
[TBL] [Abstract][Full Text] [Related]
11. Epoetin alfa as a supportive measure in hematologic malignancies.
Straus DJ
Semin Hematol; 2002 Oct; 39(4 Suppl 3):25-31. PubMed ID: 12447849
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: results of a randomized, double-blind, placebo-controlled trial.
Vincent JL; Spapen HD; Creteur J; Piagnerelli M; Hubloue I; Diltoer M; Roman A; Stevens E; Vercammen E; Beaver JS
Crit Care Med; 2006 Jun; 34(6):1661-7. PubMed ID: 16607233
[TBL] [Abstract][Full Text] [Related]
13. Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study.
Aapro M; Leonard RC; Barnadas A; Marangolo M; Untch M; Malamos N; Mayordomo J; Reichert D; Pedrini JL; Ukarma L; Scherhag A; Burger HU
J Clin Oncol; 2008 Feb; 26(4):592-8. PubMed ID: 18235117
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma.
Dammacco F; Castoldi G; Rödjer S
Br J Haematol; 2001 Apr; 113(1):172-9. PubMed ID: 11328297
[TBL] [Abstract][Full Text] [Related]
15. A multi-center open-labeled study of recombinant erythropoietin-beta in the treatment of anemic patients with multiple myeloma, low-grade non-Hodgkin's lymphoma, or chronic lymphocytic leukemia in Chinese population.
Yang S; Jun M; Hong-Li Z; Jian-Min W; Chun W; Lu-Gui Q; Yong-Qiang Z; Jun Z; Jian H; Zhi-Xiang S
Int J Hematol; 2008 Sep; 88(2):139-144. PubMed ID: 18629603
[TBL] [Abstract][Full Text] [Related]
16. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study.
Hedenus M; Birgegård G; Näsman P; Ahlberg L; Karlsson T; Lauri B; Lundin J; Lärfars G; Osterborg A
Leukemia; 2007 Apr; 21(4):627-32. PubMed ID: 17252006
[TBL] [Abstract][Full Text] [Related]
17. Once-weekly epoetin beta therapy in patients with solid tumours and chemotherapy-induced anaemia: a randomized, double-blind, dose-finding study.
Heras P; Kritikos K; Hatzopoulos A; Mitsibounas D
Eur J Cancer Care (Engl); 2008 Nov; 17(6):619-23. PubMed ID: 18707619
[TBL] [Abstract][Full Text] [Related]
18. Once-weekly dosing of epoetin-alpha increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy.
Shasha D; George MJ; Harrison LB
Cancer; 2003 Sep; 98(5):1072-9. PubMed ID: 12942577
[TBL] [Abstract][Full Text] [Related]
19. Recombinant human erythropoietin, epoetin beta, in patients with relapsed lymphoma treated with aggressive sequential salvage chemotherapy--results of a randomized trial.
Glossmann JP; Engert A; Wassmer G; Flechtner H; Ko Y; Rudolph C; Metzner B; Dörken B; Wiedenmann S; Diehl V; Josting A
Ann Hematol; 2003 Aug; 82(8):469-475. PubMed ID: 12910374
[TBL] [Abstract][Full Text] [Related]
20. A new dose-intense epoetin alfa regimen effective in anemic cancer patients receiving chemotherapy: an open-label, non randomized, pilot study.
Santini D; Vincenzi B; La Cesa A; Virzi V; Navajas F; Malafarina V; Dicuonzo G; Cassandro R; Esposito V; Montesarchio V; Groeger AM; Tonini G
Anticancer Res; 2005; 25(1B):669-74. PubMed ID: 15816644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
